GlassScriptPhysician profile
Biren G Shah
NPI 1710086533
$1,395.51
in general payments reported to CMS, 2019-2025
19 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $63.46 · 2022: $13.02 · 2024: $308 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $238.97 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $200.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $184.24 | 2019-2024 | Trelegy Ellipta, Bexsero, Shingrix |
| Lilly USA, LLC | $160.25 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $117.46 | 2019-2024 | |
| Amgen INC. | $104.55 | 2019-2025 | Otezla, Repatha |
| Mayne Pharma Commercial LLC | $64.75 | 2025 | |
| Janssen Pharmaceuticals, INC | $44.64 | 2019 | |
| Astellas Pharma US INC | $42.77 | 2019-2020 | |
| Sanofi Pasteur INC. | $39.48 | 2019-2024 | |
| Lundbeck LLC | $27.79 | 2024 | Rexulti |
| Nalpropion Pharmaceuticals LLC | $26.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.91 | 2019 | |
| Amarin Pharma, INC. | $24.87 | 2019 | |
| Valeritas, INC. | $23.61 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $20.60 | 2019 | |
| Amag Pharmaceuticals, INC. | $19.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.86 | 2025 | Jardiance |
| Allergan, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biren Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.